Full Press Release Details
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA.
LXRX
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Key Takeaway: Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Price reaction · baseline $0.7717 (2024-11-21 close) · hit after-hours · 2 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+11.9%
day 1
+5.4%
day 3
+4.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus